MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

CSBR

5.69

+2.34%↑

Search

Anavex Life Sciences Corp

Cerrado

SectorSanidad

3.06 8.13

Resumen

Variación precio

24h

Actual

Mínimo

2.82

Máximo

3.08

Métricas clave

By Trading Economics

Ingresos

4.1M

-5.7M

Empleados

34

EBITDA

3.1M

-6.8M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+609.22% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

23M

411M

Apertura anterior

-5.07

Cierre anterior

3.06

Noticias sobre sentimiento de mercado

By Acuity

17%

83%

32 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 mar 2026, 23:15 UTC

Noticias de Eventos Importantes

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mar 2026, 22:36 UTC

Noticias de Eventos Importantes

Australian Government Rules Out Boots on the Ground in the Middle East

30 mar 2026, 22:13 UTC

Adquisiciones, fusiones, absorciones

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mar 2026, 21:00 UTC

Ganancias

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mar 2026, 20:15 UTC

Noticias de Eventos Importantes

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mar 2026, 23:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 23:40 UTC

Charlas de Mercado

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mar 2026, 23:36 UTC

Charlas de Mercado

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mar 2026, 23:12 UTC

Charlas de Mercado

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mar 2026, 22:49 UTC

Charlas de Mercado

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mar 2026, 22:44 UTC

Charlas de Mercado

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mar 2026, 22:43 UTC

Charlas de Mercado

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mar 2026, 22:42 UTC

Charlas de Mercado

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mar 2026, 22:18 UTC

Charlas de Mercado

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mar 2026, 22:05 UTC

Charlas de Mercado

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mar 2026, 21:58 UTC

Adquisiciones, fusiones, absorciones

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mar 2026, 21:39 UTC

Adquisiciones, fusiones, absorciones

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mar 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mar 2026, 21:36 UTC

Adquisiciones, fusiones, absorciones

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Adquisiciones, fusiones, absorciones

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mar 2026, 21:25 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 21:25 UTC

Charlas de Mercado

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mar 2026, 21:03 UTC

Adquisiciones, fusiones, absorciones

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 mar 2026, 20:09 UTC

Ganancias

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mar 2026, 20:00 UTC

Noticias de Eventos Importantes

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

609.22% repunte

Estimación a 12 Meses

Media 20 USD  609.22%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

32 / 349 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat